

TABLE OF CONTENTS

November 23, 2009

No. 2165

BUSINESS

- 1 Plavix Drives Business of sanofi-aventis in Japan: President P. Chocat
 - Sales Up to 1,352 Mil. Euro in 3 Qtrs
- 2 Yakult Aims at ¥10 Bil. Sales for Elplat with Stomach Cancer
 - PIII for Stomach Cancer to Start in January
 - Pharmaceutical Sales Up 3.7% Driven by Elplat
- 3 Astellas to Overcome Prograf, Harnal Patent Expiration with New Products: President Nogimori
 - Mirabegron to Be Filed in 1st Half of FY2010 in Japan
 - SGLT-2 Inhibitor Esters PIII in Japan
 - Astellas Transfers Bioengineering Research Lab.
- 4 Half-Year Business Results of Domestic Companies: 3
 - Santen: License Fees Boost Operating Profits Up 237%
 - Kyorin: Sales Up 13.5% Driven by Kipres
 - Kissei: Sales Driven by Urief
 - Nippon Shinyaku: Sales Down 5.9%
 - Zeria: Sales Up Driven by OTC Drugs
 - Fuso: Operating Profits Down 56.6%
 - Seikagaku: Sales Up 4.6% Driven by Mainstay Products
 - Tsumura: Record-High Profits Due to Good Sales of *Kampo* Medicines
 - Meiji Seika: Pharma Business Up 3.2% Driven by Generics
- 7 Astellas Licenses Linaclotide from Ironwood
- 7 Nippon Kayaku Licenses Apaziquone from Spectrum
- 8 Top-Five Wholesalers' Operating Profits Down 19% Despite 6.6% Increase in Sales
 - Suzuken: Wholesale Business Returns to the Black
 - Toho: SGA Expense Rate Below 6% for the First Time
- 10 Banyu to Recommend Januvia in First-Line Therapy
- 10 **TOPICS**
 - Haruo Naito Appointed as President of the IFPMA
- 10 **BUSINESS NEWS IN BRIEF**
 - Merck's Merger with Schering-Plough Completed
 - Sanofi-aventis, Micromet Sign License Agreement for BiTE Antibody
 - Daiichi Sankyo Terminates Levofloxacin Patent Litigation
 - Freund Creates Subsidiary in Europe

GENERIC

- 12 NHI Price Listing for 394 Generic Products Announced
 - Largest Number of Products Listed by Sawai
 - Oral Liquid Formulation Listed for Levofloxacin
- 15 Strong Growth in Sales, Profits Reported by Top-4 Generic Makers
- 16 Half-year Business Results for Leading Generic Makers
 - Sawai: Sales to DPC Hospitals Drive Business
 - Towa: OD Tablets of Amlodipine Push Sales
 - Taiyo: Injectables via Wholesalers Show Strong Sales
- 17 Univ. Hospitals Should Use More Generics: Mr Isobe

REGULATORY

- 18 GRU WG Reviews Gov't Projects for Saving
- 18 Re-price Long-Listed Drugs Looking at Prices of Generics: WG
 - Cut Prices of Long-Listed Drugs to the Same Level as Generics: Mr Osa
- 19 No Conclusion on 2% Price Adjustment Range
 - WG Recommends Exclusion of OTC Drug-Like Drugs from Insurance Coverage
 - *Koroshō* Obligated to Consider Cutting NHI Prices of Long-Listed Drugs: Mr Isobe
 - Tsumura Optimistic about Insurance Coverage of *Kampo* Medicines: President Yoshii
- 20 *Chuikyo* Members Split about How to Respond to GRU WG's Recommendation
- 21 FPMAJ's Proposal Is a Package Deal: Mr Hasegawa
- 21 Mr Miura to Represent Pharmacists Because of His Business Experience at Hospital
- 22 **REGULATORY NEWS IN BRIEF**
 - Novartis Applies for New-Type Influenza Vaccine
 - Seibule Approved for Combination with Biguanides
 - Avastin Approved for NSCLC in Japan: Chugai
 - Fludara Obtains Different Additional Indications for Tablet and Injectable
 - Farletuzumab to Be Applied for in FY2012 in US: Eisai

R&D

- 22 **R&D NEWS IN BRIEF**
 - Subcutaneous Velcade in PIII in US: Takeda
 - Nexavar Enters PIII for Non-Responsive Thyroid Cancer: Bayer, Onyx
 - PI for Sancuso Completed in Japanese Volunteers: Solasia